Difference between revisions of "Part:BBa K5302035"

 
 
(2 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
<partinfo>BBa_K5302035 short</partinfo>
 
<partinfo>BBa_K5302035 short</partinfo>
  
−
This work is derived from pBBR-OmpA-VEGFR1D2 and pUC19-VEGFR-masking#29, and it has undergone codon optimization. This composite part combines OmpA(21.4kda) and VEGFR1D2(approximately 12kda), and it adds a fragment as a mask. We succeeded in transferring this plasmid into Escherichia coli Nissle 191 and let it express VEGFR1D2. The plasmid uses lac promotor and has kanamycin resistence.
+
This work is derived from pBBR-OmpA-VEGFR1D2 and pUC19-VEGFR-masking#29, and it has undergone codon optimization. This composite part combines OmpA(21.4kda) and VEGFR1D2(approximately 12kda), and it adds a fragment as a mask. We succeeded in transferring this plasmid into Escherichia coli Nissle 1917 and let it express VEGFR1D2. The plasmid uses lac promotor and has kanamycin resistence.
 +
 
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-p-o-vegfr1d2-l229-1.png"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 1. </b> Colony PCR results of pBBR-OmpA-VEGFR1D2-l2masking#29
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
 +
 
 +
<hr>
 +
 
 +
This linear 13-mer peptide is derived from the N-terminal amino acids of Vascular Endothelial Growth Factor (VEGF) and forms a helix structure. It exhibits high affinity for VEGFR-like receptors, with an IC50 value of 0.05 &#956;M, allowing it to effectively compete with VEGF for binding to VEGFR. Consequently, this peptide has been utilized as a masking agent. Upon administration into the human body, it preemptively binds to VEGFR, preventing VEGF from engaging with the receptor.
 +
Given that matrix metalloproteinases (MMPs) are present at high concentrations in the tumor microenvironment (TME), they can degrade this VEGFR-masking peptide (designated as #29). This degradation allows VEGF to subsequently bind to the VEGFR-like receptors, triggering their activation. Therefore, this peptide functions as a biological switch, becoming active when exposed to the TME upon the entry of engineered chimeric nanoparticles ( Escherichia coli Nissle 1917).
 +
 
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-vegfr-mask-29-1.png"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 2. </b> Dose–response curve for compound 29
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
 +
 
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-vegfr-mask-29-2.png"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 3. </b> VEGFR-mask-#29, from α-fold
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
 +
 
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-vegfr-mask-29-3.png"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 4. </b> The binding site of D2 and the mask can be identified as being identical to the binding site of D2 with VEGF, indicating that they can compete for binding. The linker employed consists of five repeats of the GGGGS sequence, from α-fold
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
 +
 
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-vegfr-mask-29-4.png"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 5. </b> The linker has been reduced to three repeats of the GGGGS sequence, from α-fold
 +
 
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
 +
 
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-vegfr-mask-29-5.png"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 6. </b> The linker has been modified by replacing the middle GGGGS sequence with a matrix metalloproteinase (MMP) recognition sequence, while maintaining the binding site unchanged, from α-fold
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here

Latest revision as of 02:23, 2 October 2024


pBBR-OmpA-VEGFR1D2-l2masking#29

This work is derived from pBBR-OmpA-VEGFR1D2 and pUC19-VEGFR-masking#29, and it has undergone codon optimization. This composite part combines OmpA(21.4kda) and VEGFR1D2(approximately 12kda), and it adds a fragment as a mask. We succeeded in transferring this plasmid into Escherichia coli Nissle 1917 and let it express VEGFR1D2. The plasmid uses lac promotor and has kanamycin resistence.

Jamboree Program
Figure 1. Colony PCR results of pBBR-OmpA-VEGFR1D2-l2masking#29

This linear 13-mer peptide is derived from the N-terminal amino acids of Vascular Endothelial Growth Factor (VEGF) and forms a helix structure. It exhibits high affinity for VEGFR-like receptors, with an IC50 value of 0.05 μM, allowing it to effectively compete with VEGF for binding to VEGFR. Consequently, this peptide has been utilized as a masking agent. Upon administration into the human body, it preemptively binds to VEGFR, preventing VEGF from engaging with the receptor. Given that matrix metalloproteinases (MMPs) are present at high concentrations in the tumor microenvironment (TME), they can degrade this VEGFR-masking peptide (designated as #29). This degradation allows VEGF to subsequently bind to the VEGFR-like receptors, triggering their activation. Therefore, this peptide functions as a biological switch, becoming active when exposed to the TME upon the entry of engineered chimeric nanoparticles ( Escherichia coli Nissle 1917).

Jamboree Program
Figure 2. Dose–response curve for compound 29

Jamboree Program
Figure 3. VEGFR-mask-#29, from α-fold

Jamboree Program
Figure 4. The binding site of D2 and the mask can be identified as being identical to the binding site of D2 with VEGF, indicating that they can compete for binding. The linker employed consists of five repeats of the GGGGS sequence, from α-fold

Jamboree Program
Figure 5. The linker has been reduced to three repeats of the GGGGS sequence, from α-fold

Jamboree Program
Figure 6. The linker has been modified by replacing the middle GGGGS sequence with a matrix metalloproteinase (MMP) recognition sequence, while maintaining the binding site unchanged, from α-fold

Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal EcoRI site found at 2367
    Illegal XbaI site found at 1296
    Illegal PstI site found at 123
    Illegal PstI site found at 1284
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal EcoRI site found at 2367
    Illegal PstI site found at 123
    Illegal PstI site found at 1284
    Illegal NotI site found at 5299
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal EcoRI site found at 2367
    Illegal BglII site found at 6045
    Illegal BamHI site found at 1302
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal EcoRI site found at 2367
    Illegal XbaI site found at 1296
    Illegal PstI site found at 123
    Illegal PstI site found at 1284
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal EcoRI site found at 2367
    Illegal XbaI site found at 1296
    Illegal PstI site found at 123
    Illegal PstI site found at 1284
    Illegal NgoMIV site found at 574
    Illegal NgoMIV site found at 857
    Illegal NgoMIV site found at 3025
    Illegal AgeI site found at 1955
    Illegal AgeI site found at 2865
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI.rc site found at 5621
    Illegal SapI.rc site found at 423
    Illegal SapI.rc site found at 633